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Understanding the interactions between human immunodeficiency virus type 1 (HIV-1) virions and antibodies
(Ab) produced during acute HIV-1 infection (AHI) is critical for defining antibody antiviral capabilities. Antibodies
that bind virions may prevent transmission by neutralization of virus or mechanically prevent HIV-1 migration
through mucosal layers. In this study, we quantified circulating HIV-1 virion-immune complexes (ICs), present in
approximately 90% of AHI subjects, and compared the levels and antibody specificity to those in chronic infection.
Circulating HIV-1 virions coated with IgG (immune complexes) were in significantly lower levels relative to the viral
load in acute infection than in chronic HIV-1 infection. The specificities of the antibodies in the immune complexes
differed between acute and chronic infection (anti-gp41 Ab in acute infection and anti-gp120 in chronic infection),
potentially suggesting different roles in immunopathogenesis for complexes arising at different stages of infection.
We also determined the ability of circulating IgG from AHI to bind infectious versus noninfectious virions. Similar
to a nonneutralizing anti-gp41 monoclonal antibody (MAb), purified plasma IgG from acute HIV-1 subjects bound
both infectious and noninfectious virions. This was in contrast to the neutralizing antibody 2G12 MAb that bound
predominantly infectious virions. Moreover, the initial antibody response captured acute HIV-1 virions without
selection for different HIV-1 envelope sequences. In total, this study demonstrates that the composition of immune
complexes are dynamic over the course of HIV-1 infection and are comprised initially of antibodies that nonselec-
tively opsonize both infectious and noninfectious virions, likely contributing to the lack of efficacy of the antibody
response during acute infection.
The major challenge to development of a successful human
immunodeficiency virus type 1 (HIV-1) preventive vaccine is
an incomplete understanding of the correlates of protective
immunity to HIV-1 infection. A clear understanding of the
early in vivo events following HIV-1 transmission, especially
the short time window from transmission to the establishment
of the latent pool of HIV-1-infected CD4 T cells, is critical to
the design of a protective vaccine (reviewed in reference 26).
Details of the earliest host-pathogen interactions can provide
insights into the challenges that the initial immune response
may face during transmission and establishment of infection.
We have previously reported that the first detectable B-cell
response to HIV-1 in acute HIV-1 infection (AHI) is in the
form of immunoglobulin (Ig)–HIV-1 virion immune complexes
(ICs) approximately 8 days after the time of the first detectable
plasma viral load (T0; 100 copies/ml). The appearance of
plasma ICs is followed by the HIV-1-specific virus-free plasma
antibody (Ab) against HIV-1 Env gp41, a median of 13 days
post-T0 (44).
Antibodies induced by viral infections can contribute to an-
tiviral immunity by directly neutralizing free virus particles,
activating complement, mediating opsonization and phagocy-
tosis, and facilitating Ab-dependent cellular cytotoxicity
(ADCC) (42, 43). ICs in HIV-1 infection have numerous bio-
logical consequences that depend in part on the binding of the
Fc region of IgG to Fc receptors on the surfaces of antigen-
presenting cells (e.g., macrophages and dendritic cells) or nat-
ural killer (NK) cells and also depend on the antigen specificity
of the antibody. FcRIIa was associated with the progression
of HIV-1 infection in vivo (13), and FcR alleles were associated
with protection in a Vax004 vaccine trial (12), suggesting that
Fc receptor-mediated activities do contribute to control of
HIV-1. Opsonization of virions by complement may also be an
important component of viral pathogenesis since CD21 on B
cells can bind complement-coated virions and propagate infec-
tion of T cells (27), although HIV-1 virions also incorporate
host complement inhibitor molecules during virion budding
(37). Others have also found that antibody-opsonized HIV-1
without the presence of complement components could en-
hance HIV-1 infection in vitro (2, 3, 18).
The initial induced HIV-1-specific antibodies do not exhibit
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traditional neutralizing activity, do not mediate antibody-de-
pendent cellular viral inhibition (ADCVI), do not drive HIV-1
Env escape mutations, and do not impact initial viral load
dynamics (42). Thus, a critical question is whether the initial
gp41 Env IgG response captures infectious virions, and if so,
are a sufficient proportion of virions coated with Env antibody
in AHI to potentially mediate an antiviral effect? To address
these questions, we have quantified plasma IgG-virion ICs,
determined the proportion of virions bound to IgG during
AHI, determined the kinetics of the production of acute ICs,
and determined the ability of acute HIV-1-purified IgG from
AHI to bind infectious virions in vitro. We found that 89.5% of
AHI subjects had plasma IgG-virion immune complexes. Dur-
ing acute infection, a median 22.1% of plasma viral RNA was
opsonized by IgG (forming IgG-virion immune complexes),
and the predominant IgG antibodies coating circulating
plasma virions were anti-gp41 antibodies. Thus, circulating
plasma virions in AHI are opsonized with antibodies that are
of narrow specificity, of limited magnitude, and unable to con-
trol the initial spread of HIV-1.
MATERIALS AND METHODS
Ethics statement. This CHAVI Acute and Chronic Cohorts study was re-
viewed and approved by the institutional review boards of Duke University
Medical Center. All participants provided written informed consent for study
participation.
Acute and chronic HIV-1 subjects. A total of 209 samples (3 to 9 time points
per subject) from 38 AHI subjects (plasma donors [ZeptoMetrix Corp. and
SeraCare Life Sciences] and acute CHAVI 001 cohorts) and 10 chronic HIV-1
subjects from CHAVI 001 were examined. These cohorts have been previously
described (15, 40, 44).
Plasma viral load. Plasma viral RNA was measured by Quest Diagnostics
(Lyndhurst, NJ) (HIV-1 RNA PCR Ultra). Plasma viral RNA for the quantifi-
cation was also measured by in-house HIV-1 Gag real-time RT-PCR, as previ-
ously described (44).
Cells and replication-competent reporter viruses. The 5.25.EGFP.Luc.M7
(M7-Luc) (provided by N. R. Landau, the Salk Institute for Biological Studies,
La Jolla, CA) is a CEMx174 cell clone that was produced by retroviral vector
transduction to express CCR5 (CD4 and CXCR4 are expressed naturally) and
transfection to contain Tat-responsive luciferase (Luc) and green fluorescence
protein (GFP) reporter genes. The cells were grown in RPMI 1640, supple-
mented with 12% fetal bovine serum (FBS), 50 g/ml Geneticin (G418), 0.5
g/ml puromycin, 1% Pen/strep, and 200 g/ml hygromycin (8). Replication-
competent virus stocks from infectious molecular clones (IMC) of Renilla lucif-
erase (LucR) reporter viruses (designated NL-LucR.T2A-Env.ecto) (9) express-
ing envelope regions from lab-adapted NL4-3 or transmitted/founder viruses
(CH040 and WITO) (19) were generated as described previously (9, 14). Briefly,
proviral DNA was transfected into 293T cells by Fugene HD (Roche). Working
stocks were amplified by passaging virus in human peripheral blood mononuclear
cells (PBMCs) (American Red Cross). Virus supernatants were collected every
2 or 3 days and filtered through a 0.45-m syringe filter, and titers were deter-
mined on TZM-bl cells (obtained through the NIH AIDS Research and Refer-
ence Reagent Program, Division of AIDS, NIAID, NIH, from John C. Kappes,
Xiaoyun Wu, and Tranzyme, Inc.). Wild-type HIV-1 MN was amplified by the
H9 cell line (obtained from the NIH AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH, from Robert Gallo).
HIV-1-specific binding antibody assay. Plasma HIV-1-specific antibodies were
measured by a custom HIV-1 binding antibody multiplex assay as previously
described (44). HIV-specific Ab isotypes were detected with mouse-anti human
IgG (Southern Biotech, Birmingham, AL), conjugated to phycoerythrin, at 4
g/ml. Antibody measurements are acquired on a Bio-Plex instrument (Bio-Rad,
Hercules, CA), and the readout is in mean fluorescent intensity (MFI) or g/ml
equivalents based on a 2F5 MAb (Polymune Scientific, Vienna, Austria) stan-
dard curve for gp41 IgG detection (5-PL curve fitting) using 21CFR part 11-
compliant software. All assays were run under good clinical laboratory practice
(GCLP)-compliant conditions, including tracking of positive controls by Levy-
Jennings charts. Positivity criteria for antibody-antigen pairs were predetermined
using a set of plasmas from 30 seronegative subjects (mean MFI  standard
deviation [SD] of 3).
Quantitative IgG-HIV-1 virion immune complex assay. IgG–HIV-1 virion (IC)
were measured by protein G absorption. Briefly, plasma was centrifuged
(10,000  g) for 10 min to remove cellular debris and filtered in a 1.2-m filter
plate (Pall AcroPrep). The 150-l filtered samples were loaded on each well in
protein G HP MultiTrap 96-well plates (GE Healthcare, Inc.) and incubated 1 h
with shaking. After incubation, the plate was centrifuged at 1,500  g for 3 min.
The flowthrough fraction was harvested. After washing to remove nonspecific
bound material, the absorbed IgG-virion IC was lysed by 560 l AVL lysis buffer
from the QIAmp viral RNA minikit (Qiagen, Inc.) and was harvested by centri-
fuging 1,500  g for 3 min. The viral RNA in the lysis buffer was purified with the
QIAmp viral minikit according to the manufacturer’s instructions. The viral
RNA present in each fraction was measured by HIV-1 Gag real-time RT-PCR.
Briefly, the one-step RT-PCR amplification reactions were performed in a
MicroAmp optical 96-well plate (Applied Biosystems, Foster City, CA) in a 25-l
reaction mixture containing 1 one-step TaqMan RT-PCR master mix, 900 nM
forward and reverse primers, 200 nM probe, and the template RNA in a final
volume of 25 l. Reverse transcription was performed at 48°C for 30 min and was
followed by activation of TaqGold at 95°C for 10 min. Subsequently, 40 cycles of
amplification were performed at 95°C for 15 s and 60°C for 1 min. Polyclonal
HIV immunoglobulin (HIVIG) obtained from the NIH AIDS Research & Ref-
erence Reagent Program (ARRRP) and the HIV broadly neutralizing antibody
2G12 MAb (Polymune Scientific, Vienna, Austria) were utilized as positive
controls. The negative controls, normal human serum (NHS) (Sigma), and virus-
only control were utilized to establish the positivity cutoff. We utilized the
mean  5 SD of the NHS negative control to calculate the positivity cutoff of
8.6% (NHS mean  5 SD).
Plasma IgG purification. IgG was isolated from plasma using the protein G
HP MultiTrap 96-well plates described above (GE Healthcare, Inc.). Briefly,
plasma was 2-fold diluted with Tris-buffered saline (TBS) at pH 7.5, and 200 l
of diluted plasma was incubated in the plates for 1 h. Unbound fractions were
removed by centrifugation at 1,500  g for 3 min. Wells were then washed 3
times with 200 l of TBS. IgG was eluted with 2.5% glacial acetic acid and
immediately neutralized with 120 l of 1 M Tris-HCl, pH 9.0. The eluted IgG
fractions were concentrated and desalted using Amicon Ultra centrifugal filters
(Millipore) with a 30,000 cutoff at 14,000  g for 12 min. The IgG was then
concentrated to the desired volume and assayed for protein concentration using
a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific).
Protein G capture of virus particles and infectious HIV-1 virions. Purified
plasma IgG or monoclonal IgG was mixed with 1  107 RNA copies/ml NL-
LucR.T2A viral stock at a final concentration of 10 g/ml in 300 l. The IgG and
virion IC mixture were prepared in vitro and absorbed by a protein G MultiTrap
96-well plate as described in the measurement of endogenous IgG–HIV-1 virion
IC described above. The virions in the flowthrough or captured fraction were
measured by viral RNA with HIV-1 Gag real-time RT-PCR, and the 25-l
flowthrough or input was used to infect TZM-bl cells. Infection was measured by
a firefly luciferase assay at 48 h postinfection as described previously (39). Briefly,
100 l supernatant was removed, and 100 l Britelite (Perkin Elmer) was added
to each well. After 2-min incubation, the 150-l lysis was used to measure HIV-1
replication as expressed as relative luciferase units (RLUs). Each sample was run
in triplicate. The percentage of viral particles in the flowthrough or capture
fraction was calculated as flowthrough or capture RNA/(flowthrough  cap-
ture)  100%. The percentage of infectivity was calculated as flowthrough
infectivity/input infectivity  100%. The positive controls HIVIG and 2G12
MAb gave virus capture of 66.1  3.7% at 0.83 mg/ml and 30.1  1.4% at 10
g/ml, respectively. The negative controls, NHS (Sigma), HIV-1 IgG (purified
IgG from HIV-1-negative donors [Sigma]), G8 MAb (an IgG monoclonal anti-
body derived from an Epstein-Barr virus (EBV)-transformed B cell, provided by
Kwan-Ki Hwang, Duke University [23]), and virus-only controls were utilized to
establish the positivity cutoff. The means  5 SD of G8 MAb and virus only are
4.43% and 6.35%, respectively. We utilized the mean  5 SD of the NHS-
negative control to calculate the positivity cutoff of 8.6% (NHS mean  5 SD).
Infectious virus capture assay. To measure the captured infectious IC, we
adopted the Ig-virus capture assay described previously (44). Briefly, microplates
(Nunc) were coated overnight at 4°C with mouse monoclonal anti-human IgG
(Southern Biotech, Birmingham, AL) at a concentration of 1 g/ml diluted in
PBS. After coating and washing, coated plates were blocked for 2 h with PBS
supplemented with 5% goat serum, 5% milk, 0.05% Tween. The indicated
concentration of antibodies was mixed with the viral stock containing 5  106
viral RNA and then centrifuged 90 min at 2,000 rpm. Then the mixture was
centrifuged at 21,000  g for 45 min at 4°C to remove the virus-free antibody
(22), and the pellet was resuspended in the same volume of PBS. A total of 50
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l of the IC mixture was added to each coated well in triple wells for a 90-min
incubation. Then, the wells were washed 4 times, and the indicator cell line
(M7-luc or TZM-bl) was added. HIV-1 replication was assessed on day 5 after
infection for M7-luc and on day 3 for TZM-bl. The infection was measured by
the firefly luciferase assay and was expressed as RLU.
Antibody adsorption assay. A total of 2.4 g total-plasma-purified IgG was
incubated with 0.36  106 carboxylated fluorescent beads conjugated with 1.5 g
HIV-1 MN gp41 (ImmunoDiagnostics, Woburn, MA), gp120 protein, or a blank
(Luminex Corp, Austin, TX) for 1.5 h. After incubating for 1.5 h, beads were
centrifuged for 2 min at 8,000  g, and the supernatant was harvested. The
absorption was repeated another two times. The supernatant was used to make
the IgG-virion IC mixture in vitro, and the infectious IgG-virion IC captured by
coated anti-human IgG was measured by an M7-luc assay as described above.
The HIV-1 anti-gp41 IgG depletion efficiency of absorbed supernatant was
confirmed to be removed of HIV-1-specific antibodies by the HIV-1-specific
binding antibody assay as described above.
SPR. Surface plasmon resonance (SPR) binding assays were performed on a
BIAcore 3000 (BIAcore, Inc., Piscataway, NJ) instrument at 25°C, and data
analyses were performed using BIAevaluation 4.1 software (BIAcore) as previ-
ously described (1). HIV-1 MN gp41 and a control protein, HIV-1 p66, were
coupled covalently on individual flow cells from 5,000 to 7,000 RU on a BIAcore
CM5 sensor chip as described previously (1). IgG samples (100 g/ml) were
injected at 10 l/min for 2 min and allowed to dissociate in running buffer (PBS
[pH 7.4], 0.005% P20) for 10 min. Bound complexes were regenerated by 10 l
glycine-HCl, pH 2.0, at 50 l/min. Rate constants for HIV-1-specific IgG binding
were measured using a 1:1 Langmuir dissociation model (1). The off rate (or
dissociation rate) expressed as 1/Kd in seconds is reported.
Single-genome amplification and sequence analysis of the HIV env gene. Viral
RNA from the flowthrough or captured fraction was extracted using the
PureLink viral RNA/DNA minikit (Invitrogen, Carlsbad, CA) and reverse tran-
scribed into cDNA using Superscript III (Invitrogen, Carlsbad, CA) and primer
1.R3.B3R 5-ACTACTTGAAGCACTCAAGGCAAGCTTTATTG-3 (nucleo-
tides [nt] 9611 to 9639 in HXB2) in a 50-l volume. Single-genome amplification
(SGA) was used to obtain rev-vpu-env cassettes as previously described (19, 21).
The first-round PCR was carried out with primer 07for7 5-CAAATTAYAAA
AATTCAAAATTTTCGGGTTTATTACAG-3 (nt 4875 to 4912 in HXB2) and
antisense primer 2.R3.B6R 5-TGAAGCACTCAAGGCAAGCTTTATTGAG
GC-3 (nt 9608 to 9636 in HXB2); the second-round PCR was carried out with
sense primer VIF1 5-GGGTTTATTACAGGGACAGCAGAG-3 (nt 4900 to
4923 in HXB2) and antisense primer LOW2C 5-TGAGGCTTAAGCAGTGG
GTTCC-3 (nt 9591 to 9612 in HXB2). All SGA amplicons were sequenced
directly by cycle sequencing and dye terminator methods using an ABI 3730xl
genetic analyzer (Applied Biosystems, Foster City, CA). Individual sequences
were assembled and edited using the Sequencher program 4.7 (Gene Codes, Ann
Arbor, MI). The env sequences were aligned using CLUSTAL W (41), and
manual adjustment for optimal alignment was done using MASE (10). A phy-
logenetic tree was constructed with complete env gene sequences using the
neighbor-joining method (38) and the Kimura two-parameter model (20). High-
lighter analysis was performed through the LANL database website (http://www
.hiv.lanl.gov/content/sequence/HIGHLIGHT/highlighter.html).
Quantity of HIV-1 antibodies in HIV-1 virion-IgG complexes during AHI. To
study the relationship between the concentration of anti-gp41 IgG and the
percentage of viral load bound in the plasma of acutely infected patients, we
assumed the following dynamics between antibodies and virions: A  V N C.
Antibodies A reversibly bind to free virions V to form an antibody-virion complex
C. Since the binding is reversible, antibodies can dissociate from the complex.
We assume that the binding kinetics are much faster than the changes in anti-
body concentration or viral load over time, leading to the following quasi-steady-
state assumption: Kb  AV  Kd  C or C  K  AV, where Kb and Kd denote the
binding and dissociation rate constants, respectively, and Kb/Kd  Ke, the (ef-
fective) affinity constant of the antibody studied. With VT  V  C defining the



























where f denotes the total number of antibodies than can simultaneously bind a
virion, K is the affinity of an antibody for one gp41 on the virion (i.e., the true
affinity), and Ci(t) is the concentration of virions with i antibodies bound at time t.
Statistical analysis. The statistical significance between the mean values of the
endogenous HIV-1 IgG-virion IC for the acute subjects and the chronic subjects
was determined by an unpaired two-tailed t test. To determine the correlation
between levels of HIV-1 plasma VL and the plasma HIV-1 IgG-virion IC, a
linear regression analysis was performed, and the results were expressed as the
correlation coefficient (r). A mixed-model analysis was performed to determine
the relationship between the levels of HIV-1-specific anti-gp41 IgG and the
plasma HIV-1 IgG-virion IC. Differences were considered significant if the P
value was 0.05. All statistical analyses were performed in SAS v9.2 (SAS
Institute, Cary, NC), using CORR, GLM, and MIXED procedures.
RESULTS
Plasma HIV-1 IgG-virion immune ICs during AHI. We
characterized plasma HIV-1 IgG-virion ICs during the initial
stages of acute HIV-1 infection from 38 subjects from the
CHAVI 001 and US plasma donor cohorts (167 samples, 3 to
9 time points per subject). The plasma donor cohort had fre-
quent sampling for HIV antibody or viral RNA testing within
the first 20 days before and after T0 (15, 40, 44), and the
CHAVI 001 acute cohort had sampling near the initial VL
peak with longitudinal follow-up samples. To measure the level
of virions circulating in plasma that are coated in IgG, we
utilized a quantitative IgG–HIV-1 virion immune complex as-
say. HIV-negative NHS and a control monoclonal antibody not
specific for HIV-1 were used as negative controls, and poly-
clonal purified HIV-1 plus IgG (HIVIG) were used in every
assay. Shown in Fig. 1 are 6 representative subjects of acute
HIV-1 infection from the acute CHAVI 001 cohort that show
the rise in the percentage of IgG-coated HIV-1 virion in
plasma VL during the initial phase of AHI. The 6 subjects were
enrolled in Fiebig stages I to IV according to the classification
described by Fiebig et al. (11). In contrast, the plasma viral
load declined during this same time period. We found ICs
(comprised of the patient IgG and circulating plasma virus,
8.63%, the cutoff value, NHS  5 SD) in 34 of the 38 AHI
subjects studied (89.5% frequency of detection). The peak
endogenous IgG-virion IC level ranged from 8.6 to 73.9%,
(mean, 24.1%; median, 22.1%), indicating that a significant
proportion of plasma virions was present in the IgG-bound IC
during AHI. In four subjects (10.5%, 4/38), we could not detect
IgG-virion ICs, although in the same specimens we could de-
tect a significant quantity of viral RNA (7.24  105 to 2.82 
106 copies/ml). Importantly, there were no significant differ-
ences in the viral loads between subjects who had detectable
ICs and those that did not (IgG-virion IC-positive [IC] group:
2.35  2.51  106 copies/ml versus IgG-virion IC-negative
[IC] group: 1.62  0.93  106 copies/ml) (P  0.6, Student t
test). We also determined whether there was a relationship
between the level of immune complexes and plasma virus.
There was no correlation between the plasma viral load (RNA
copies/ml) and IgG ICs (percentage of IgG-bound plasma viral
RNA) in each sample from 38 AHI subjects (r  0.06, P 
0.41) (Fig. 2), indicating that the measurement of virus com-
plexes is not reflective of overall viral load. Additionally, there
was no correlation between the total measured plasma virus
(RNA copies/ml) and the quantity of captured virions (RNA
copies/ml) (peak response values are shown in Table S1 in the
supplemental material).
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Previous studies have demonstrated the presence of virion
IC in chronic HIV-1 plasma (7, 29). Using the same assays as
those used for AHI, we measured the plasma HIV-1 IgG-
virion ICs in plasma from 10 chronically infected subjects. In
contrast to AHI subjects, the IgG-virion ICs were detectable in
all 39 plasma specimens tested from 10 subjects over a 24- to
60-week period (100% frequency of detection). The level of
ICs in chronic plasma ranged from 17.7% to 66.9% with a
median and mean of 47.8% and 46.8%, respectively. Unlike
AHI, IgG-virion ICs in chronic subjects maintained stable lev-
els over the time period examined. For example, with patient
C1-0645, IgG-virion ICs were detectable in all samples from
week 0 to week 24 poststudy. The level of ICs ranged from
45.7% to 59.1% over 24 weeks (Fig. 3A). The quantity of
circulating virions relative to total viral RNA that were op-
sonized in IgG in chronic infection were significantly higher
than acute infection, compared to plasma samples in Fiebig
stages I to VI (P  0.0001, unpaired two-tailed t test) (Fig. 3B)
(11, 26). The absolute values for circulating immune complexes
(measured as viral RNA) ranged from 132 to 6.62  106 viral
RNA copies/ml in AHI (mean  1.33 105) and 164 to 1.37 
105copies/ml in chronic infection (mean  1.9  104). Among
those subjects who were positive for circulating HIV-1 com-
plexes (greater than or equal to 8.6%, n  37 AHI patients and
n  10 chronic patients), there was not a significant difference
(mixed-model analysis of variance [ANOVA]) in the absolute
amount of viral RNA in complexes between acute and chronic
infection. Thus, although the absolute levels of circulating vi-
rions that are opsonized by IgG are similar in acute and
chronic infection, the relative proportion of IgG-coated virions
are significantly lower in acute infection.
Plasma IgG from AHI and HIV-1 chronically infected sub-
jects capture infectious HIV-1 virions in vitro. Since circulating
plasma HIV-1 virions were opsonized by IgG in vivo, we also
asked whether the purified antibody from plasma from the
same subjects had the capacity to capture virions in vitro. Thus,
in vitro ICs were made using infectious virus and purified AHI
plasma IgG. The percentage of virus captured by purified
plasma IgG was determined by separation of opsonized virions
and nonopsonized virions using protein G columns. Both the
percentage of virions bound and the infectious potential of
IgG-bound virions were determined.
FIG. 1. Increasing proportion of acute HIV-1 plasma virions are coated by IgG. Endogenous plasma IgG-virion immune complexes in plasma
from 38 AHI subjects were measured by the use of protein G absorption. The IgG-virion immune complexes were detected in the plasma of 34
out of 38 subjects (IgG opsonized a range of 8.6 to 73.89% of plasma HIV-1 VL during AHI). Endogenous IgG-virion IC and plasma viral load
for 6 representative subjects (enrolled at Fiebig stages I to IV) are shown.
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First, physical virions were measured in both the uncaptured
(flowthrough) and the captured fraction (IgG bound) by real-
time RT-PCR. The negative control G8 MAb and virus-only
controls yielded capture of 3.5% and 2.9%, respectively (Fig.
4A and B). The positive controls included neutralizing poly-
clonal pooled IgG (HIVIG), the neutralizing antibody 2G12
MAb, and the nonneutralizing anti-gp41 monoclonal antibody
7B2 MAb (gp41 immunodominant region) (32). As shown in
Fig. 4, these antibodies captured virions containing 2.77  106
to 4.60  106 copies of viral RNA at 10 g/ml which accounted
for 65.2%, 44.8%, and 71.2% of the input viral particles for
HIVIG, 2G12 MAb, and 7B2 MAb, respectively. 7B2 MAb
reflects a specificity of anti-gp41 antibody, which is among the
first gp41 antibodies induced in AHI (44) and therefore serves
as a good control to characterize the ability of this specificity of
antibody to capture virions.
We focused further characterization of plasma IgG capture
of HIV-1 on three subjects (9075, PRB939, and C1-0586) that
had detectable anti-gp41 IgG and detectable endogenous IgG-
virion immune complexes (25.5% [25 days post-T0], 44.5% [93
days post-T0], and 55.3% [4 weeks postenrollment], respec-
tively) and that represented two subjects from acute infection
and one subject from chronic infection. Purified plasma IgG
(10 g/ml) from these three subjects were captured from
1.21  106 to 3.67  106 copies RNA of NL-LucR.T2A viral
particles and accounted for 14.4%, 62.1%, and 69.1% of the
FIG. 2. No correlation between HIV-1 plasma viral load and plasma endogenous IgG-virion IC in all samples from AHI. The plasma viral load
was plotted against the level of the endogenous plasma IgG-virion IC (r  0.06, P  0.41).
FIG. 3. The plasma endogenous IgG-virion IC in chronic subjects. (A) Unlike AHI subjects, chronic subjects maintained a high level of
endogenous IgG-virion IC over time. Approximately 50% plasma viral load was captured by IgG in the chronic subject C1-0645 over a 24-week
study period. (B) Comparison of the endogenous IgG-virion IC in acute and chronic infection. The value of endogenous plasma IgG-virion IC in
39 samples from chronic infection (10 chronic subjects) compared to 69 samples from acute infection; Fiebig stages I to VI in 34 AHI subjects are
shown here. The Fiebig stage was defined as described in reference 11. The samples from plasma donor cohort were assigned to Fiebig stages I
to VI if they were less than 30 days post-T0. The line bar represents the mean value (P values, unpaired two-tailed Student t test).
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input viral particles (Fig. 4A and B). Purified plasma IgG from
subject PRB939 (93 days post-T0) and subject C1-0586 (4
weeks poststudy) demonstrated a similar ability to capture
NL-LucR.T2A as HIVIG and the anti-gp41 monoclonal anti-
body, 7B2 MAb. The in vitro immune complex results corre-
spond with the in vivo endogenous IgG-virion IC results, in
that the ranking of the highest to the lowest quantity of im-
mune complexes was the same: C1-0586  PRB939  9075
(see Table S1 in the supplemental material). These in vitro IC
formation data support our findings that significant fractions of
circulating plasma virions can be coated with IgG in vivo.
Next, we examined whether IgG ICs contained infectious
virions. Due to the inherent difficulties in accurately assessing
the infectious nature of virus in patient plasma, either due to a
small percentage of virions being infectious (4) or due to lim-
itations in the in vitro assays (33), we determined the capacity
of IgG purified from plasma following HIV-1 transmission to
capture exogenously added infectious virions. We first tested
the amount of infectious virus that could be captured by known
neutralizing antibodies with HIV-1 specificities known to me-
diate ADCC and ADCVI. 7B2 MAb targets the immunodom-
inant region of gp41 and is nonneutralizing in the classic HIV-1
neutralization assays but represents antibodies that could have
virus inhibitory potential by other mechanisms (17). We found
that 77.6% of the infectious virus was captured by MAb 7B2
(Fig. 4C and D). Similarly, for HIVIG, a polyclonal mixture of
pooled IgG known to mediate both neutralization and ADCC,
we found that 68.9% of the infectious virus could be captured
(Fig. 4C and D). MAb 2G12, a broadly neutralizing anti-HIV-1
human MAb reactive with a high-mannose glycan cluster on
the surface of glycoprotein gp120 (6, 46), selectively bound to
virtually all infectious virions (Fig. 4). When 2G12 MAb-virion
complexes were added to the column, there were no detectable
infectious virions in the protein G-absorbed flowthrough as
determined by TZM-bl infection; however, 55% of the input
viral particles were detected in the flowthrough by measuring
viral RNA. We confirmed that 2G12 MAb was not present in
the flowthrough fraction (see Fig. S1A in the supplemental
material), and the 2G12 flowthrough did not neutralize the
infection (see Fig. S1B in the supplemental material). The
purified plasma IgG from acute HIV-1 infection captured in-
fectious virions at levels similar to those of MAb 7B2, which
targets HIV-1 gp41 Env. Moreover, the rank order of infectious
virus capture was similar to the results obtained by the virus
capture assays that measured viral RNA: chronic C1-0586 
PRB939  9075. Plasma IgG from acute plasma subject PRB939
captured up to 51% infectious virus, similar to the levels captured
by anti-gp41 nonneutralizing 7B2 MAb.
Nonselective binding of initial HIV-IgG to circulating
plasma HIV-1 virions. To address the question of whether the
initial HIV-specific IgG selectively bound certain subpopula-
tions of viral quasispecies, we obtained full-length HIV env
gene sequences by SGA from the captured virions and com-
pared the sequences to those of the uncaptured virions. Plasma
samples collected 12 weeks postenrollment (the peak of the
endogenous plasma IC) from subject C1-0358 were separated
FIG. 4. Plasma IgG from HIV-1 infection captures infectious or noninfectious HIV-1 viral particles. IgG-virion IC was prepared in vitro at final
concentration of 10 g/ml IgG, and IgG-virion IC mixture was absorbed by protein G. The viral RNA or infectivity in different fractions was
measured by HIV-1 Gag real-time RT-PCR (Fig. 4A and B) or TZM-bl infection (Fig. 4C and D). The error bar represents the standard deviation.
The percentage of virions (viral RNA) (Fig. 4A) or infectious viruses in each fraction (Fig. 4C) of the input was calculated as described in Materials
and Methods and are shown here. vRNA, viral RNA.
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by the protein G column, and the env gene sequences from the
captured and uncaptured (flowthrough) fractions were com-
pared (23 and 20 env sequences from the uncaptured and the
captured fractions, respectively). There was no distinction in
virus sequence populations between the captured and uncap-
tured viruses by the phylogenetic tree and the highlighter plots
(see Fig. S2A and B in the supplemental material). In some
cases, the env sequences from the captured fraction were iden-
tical to the sequences from the flowthrough fraction. These
results indicate that there are no genetic differences in the
envelope sequences between the uncaptured (flowthrough)
and IgG-captured viruses.
Anti-gp41 IgG is a component of plasma IgG-virion ICs.
Since the earliest detectable anti-Env IgG response after
HIV-1 transmission targets gp41 and occurs close to the
time of the first detectable endogenous HIV-1 IgG-virion
IC, we investigated if this antibody specificity was a compo-
nent of the initial IC (44). We found that the endogenous
IgG-virion ICs were detected at the same time or later than
the plasma anti-gp41 IgG in 76% (19/25) of IgG-virion IC
subjects, and the two measurements had a corresponding
increase in some subjects (Fig. 5A). The statuses of another
9 IgG-virion IC subjects were not able to be determined
because the first available time point samples were both
anti-gp41 antibody and IgG-virion IC positive. It is impor-
tant to note that the presence of plasma IgG-virion IC arose
before the appearance of anti-gp41 IgG in 24% of IgG-
virion IC subjects (6/25). This indicates that natural cross-
reactive antibodies to antigens present on HIV-1 virions or
antibodies to host molecules that are incorporated in HIV-1
virions are likely a component of the specificities that com-
prise circulating immune complexes during AHI.
Furthermore, we found that the complement component,
C3d, also opsonized plasma virions in acute infection (see Fig.
S3 in the supplemental material). For those samples collected
within 30 days post-T0 (except PRB939-09, 93 days post-T0)
and that had undetectable anti-gp120 plasma IgG in the study
period (n  8 subjects), we examined the correlation of gp41-
specific antibodies with virion-IgG complexes. In these sub-
jects, there was a significant positive correlation between anti-
gp41 IgG (g/ml) in plasma and endogenous IC (t  4.88, P 
0.0001) (Fig. 5B). Furthermore, to determine whether the
quality of anti-gp41 IgG was also associated with endogenous
IgG-virion IC, we determined the dissociation rates (Kd) as
one measure of avidity against Env gp41 of purified plasma
IgG over time by surface plasmon resonance (SPR). In 4 AHI
subjects, the increasing 1/Kd values suggested an increase in the
avidity of anti-gp41 IgG to Env gp41 antigen and paralleled the
plasma endogenous IgG-virion IC (Fig. 6A). IgG dissociation
rates against HIV-1 MN gp41 were significantly correlated
with the plasma endogenous IgG-virion IC (r2  0.76, P 
0.01) (Fig. 6B; see also Fig. S4 in the supplemental material).
This indicates that the quality (as measured by the off rate) of
HIV-1-specific IgG may play a role in the ability of gp41-
specific IgG antibodies to opsonize virions. These data strongly
suggest that HIV-1-specific anti-gp41 IgG is a component of
the plasma IgG-virion IC in vivo.
To further address the specificity of antibodies in the endog-
enous IgG-virion ICs, we measured the ability of purified
plasma IgG from selected subjects, where endogenous IgG-
virion ICs appeared at the same time or later than anti-gp41
IgG, to bind infectious virions over time. In subject PRB939,
the purified plasma IgG from the later plasma time points (day
13 and day 93 post-T0) captured infectious lab-adapted HIV-1
NL-LucR.T2A, whereas the earlier sample obtained day 11
post-T0 that was negative for anti-gp41 IgG did not capture
virus. In this subject, the levels of captured infectious NL-
LucR.T2A corresponded with the increased levels of anti-gp41
IgG in plasma (Fig. 7A), and anti-gp41 was the only detectable
specificity of antibody present in the plasma at this time point.
We also assessed the ability of gp41 antibodies to capture
virions expressing early transmitted/founder Env (19). The pu-
rified IgG from subject PRB939 (day 93 post-T0) captured
NL-LucR.T2A-WITO at a level equal to an about 1:1,000
dilution of plasma (Fig. 7B). Similar results were obtained with
another transmitted/founder virus (CH040) (not shown). The
capture of HIV-1 NL-LucR.T2A virions by purified plasma
IgG from subject PRB939 was also confirmed by measuring
HIV-1 viral RNA (3.4 104 RNA copies/g purified plasma
IgG).
FIG. 5. Circulating plasma IgG-virion immune complexes significantly correlate with the concentrations of anti-gp41 Env IgG during AHI.
(A) IgG-virion IC and anti-gp41 IgG from one typical plasma donor subject (patient 9012) is presented here. (B) Levels of log10 anti-gp41 IgG
(g/ml) in plasma significantly correlate with the level of plasma IgG-HIV-1 virion IC (n  8) (t  4.88, P  0.0001). Every log10 increase in
anti-gp41 IgG correlates to a 6.2% increase in IgG-virion IC. Each color represents one individual subject.
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Unlike plasma from AHI, plasma from chronic infection had
persistently high levels of endogenous IgG-virion ICs (Fig. 3)
and anti-gp41-specific IgG. To determine the amount of infec-
tious virus capture by antibodies in chronic infection, IgG was
purified from a series of time points (2 to 24 weeks poststudy)
from patient C1-0586 and assessed for the ability to capture
infectious HIV. The level of HIV infection ranged from 9.9 
104 to 1.5  105 RLU (Fig. 7C), and the kinetics of the ap-
FIG. 6. Endogenous plasma IgG-virion IC correlates with the dissociation rates (avidity maturation) of plasma anti-gp41 IgG. (A) The
anti-gp41 IgG avidity (off rate,1/Kd in seconds) and the endogenous plasma IgG-virion IC are shown for a representative subject during acute
infection. (B) Levels of IgG-virion IC and the anti-gp41 IgG dissociation rates significantly correlate (n  4) (r2  0.76, P  0.01). Dissociation
rates (s1) as a measure of avidity were calculated as described in Materials and Methods.
FIG. 7. Purified plasma IgG from AHI (A, B) or chronic (C) subjects captures infectious HIV-1. A total of 50 l IC mixture containing plasma IgG
at 10 g/ml and 5  106 RNA copies viral particles was added to each mouse anti-human IgG-coated well after incubation in vitro for 1.5 h. The infection
of captured IgG IC was measured by multiple-round M7-luc assay for NL-LucR.T2A at 5 days postinfection (A and C) or by TZM-bl at 3 days
postinfection for NL-LucR.T2A-WITO (B). The infectivity was measured by firefly luciferase assay and expressed as relative luciferase units (RLU). The
gray bar represents the positive or negative controls. The gray bar represents the clinical samples. The levels of anti-gp41 IgG of plasma samples (solid
line) were plotted together with the in vitro capture. The cutoff values were 3 background. All runs were performed in triplicate.
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pearance of antibodies capable of binding to virions were sim-
ilar to those of the plasma IgG-virion ICs (Fig. 7C).
In order to further confirm that anti-gp41 IgG in plasma was
responsible for the formation of HIV-1 virion ICs seen in vivo
and in vitro in AHI, the anti-gp41 IgG in the purified polyclonal
IgG of subjects PRB939 (day 93 post-T0) and 9075 (day 25
post-T0) were depleted first by anti-gp41 protein-conjugated
microspheres, before detection of IgG-virion immune com-
plexes. Depletion of gp41- or gp120-specific antibodies was
confirmed by a quantitative HIV-1 binding antibody assay
(99% depletion by gp41-conjugated beads and 90% deple-
tion by gp120-conjugated beads, respectively). For AHI 9075
and PRB939, after anti-gp41 antibody depletion by gp41-con-
jugated beads, the captured infectious NL-LucR.T2A was de-
creased by 96% and 66.7%, respectively, compared to blank
bead control; however, the depleted IgG by gp120-conjugated
beads reduced the captured infection only by 30% and 19%,
respectively (Fig. 8). These results demonstrate that the initial
anti-gp41 IgG elicited by HIV-1 transmission was the predom-
inant antibody coating HIV-1 virions. In contrast, the total
purified IgG from chronic patient C1-0586 (4 weeks poststudy)
captured virions that were competed out predominantly by
gp120 Env and not gp41 protein (Fig. 8). The depletion by
gp120-conjugated beads resulted in a 77.5% decrease in the
captured HIV-1 infection, but the depletion by gp41 beads
demonstrated only a minor 5.3% decline in infection (Fig. 8).
Similar results were found in plasma IgG depletion by HIV-1
Env-conjugated beads in chronic subject C1-0645. The infec-
tion of wild-type HIV-1 MN captured by the purified IgG of
C1-0586 week 4 declined 94% after absorbed by HIV-1 MN
Env gp120-conjugated beads; however, only a 19% decrease in
the infection was seen after gp41-conjugated bead depletion.
These results show that anti-gp120 but not anti-gp41 antibod-
ies comprise a majority of the antibodies in virion-IgG immune
complexes in these two subjects with chronic HIV-1 infection.
In contrast, gp41 antibodies are the primary mediators of IC
formation during AHI.
Quantity of IgG bound to virions in AHI. We measured the
quantity of circulating virions captured by IgG antibodies in
acute infection and identified that these IgG antibodies are
specific for gp41. This raised the question of how many anti-
gp41 antibodies coat virions during acute infection. As de-
scribed in Materials and Methods, we derived some simple
expressions for the equilibrium fraction of virions expected to
be in antibody-virion complexes when antibody is present at
concentration A(t) and has effective affinity K for gp41 on the
virion. The analysis was restricted to those 8 plasma donor
subjects that had endogenous IgG-virion ICs at the same time
or later than anti-gp41 IgG. Figure 9 shows the data and the
best fit predicted by equation 1 in Materials and Methods. The
corresponding estimated affinity constants K are shown in Ta-
ble S2 in the supplemental material. We also fitted equation 2
in Materials and Methods to the data to allow for multivalent
binding, where HIV-1 was treated as an f-valent particle (Fig.
9; see also Table S2). In addition to f  1, we examined two
different values of f, f  14, which corresponds to the average
number of HIV envelope (Env) glycoprotein spikes on a virion,
and f  35, which corresponds to the maximum number of Env
spikes (47). This approach did not improve the results signif-
icantly. As can be seen from Fig. 9, the fits with the assumption
of multivalent binding do not differ from the results obtained
by assuming only univalent binding. This, as well as the ap-
proximate linear nature of the curves in Fig. 9, suggests that
most virions are bound by only one IgG antibody. This can also
be shown formally using equation 2 and the estimated affinity
constants given in Table S2.
DISCUSSION
In this study we have shown that a median of 22% (range of
8.6% to 73.9%) of circulating plasma virions were coated by
IgG in approximately 90% of AHI subjects. In 76% of IgG-
virion IC AHI subjects, the initial HIV-1-specific anti-gp41
IgG elicited by HIV-1 infection accounted for the formation of
IgG-virion ICs in vivo and was also able to capture infectious
virions in vitro. However, in some acute HIV-1 subjects the
differential kinetics of free anti-gp41 antibodies and immune
complexes indicate that other antibodies are also likely to be
involved in forming a minority of AHI ICs. In contrast to AHI,
the plasma IgG-virion IC presented significantly higher levels
in chronic plasma. Whereas gp41 antibodies predominated in
AHI ICs, gp120 antibodies opsonize virions in plasma during
chronic HIV-1 infection.
The first free plasma antibodies in AHI are directed to gp41
Env at 13 days post-T0 and are followed by Env gp120-specific
antibodies at 1 month post-T0 (44). The initial HIV-1-elicited
antibodies are nonneutralizing and ineffective in controlling
virus replication during AHI. We have quantified the amount
of circulating plasma virions that are opsonized in AHI (me-
dian of 22%). We have also demonstrated that there is no
selection for particular HIV virions in subject C1-0358 (as
determined by SGA). Furthermore, we identified that anti-
gp41 antibodies are the predominant IgG antibody specificity
comprising these initial virus complexes. However, mathemat-
ical modeling of the antibody-virion complexes suggests that a
small number of antibodies are coating each virion compared
to the number of potential binding sites on a virion.
One of the mechanisms whereby the host defends against
incoming pathogens is to coat the pathogen with antibodies,
FIG. 8. Different specificities of antibodies in immune complexes in
acute and chronic infection. Purified plasma IgG from AHI subjects
9075 (day 25 post-T0) and PRB939 (day 93 post-T0) or chronic subject
C1-0586 (week 4 poststudy) were absorbed by Env gp41 or Env gp120-
conjugated, or blank microsphere beads. Then the absorbed superna-
tant was used to prepare IgG-virion IC mixture in vitro. The infectious
IC was captured by plates coated with anti-human IgG antibody and
was measured for infection in the M7-luc infection assay as described
above. The percentage of infection compared to the control blank bead
is shown here. The results represent at least 3 experiments.
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forming immune complexes that opsonize and mediate im-
mune clearance of the invading pathogen. Clearly, the initial
antibodies in AHI do not clear HIV-1 virions after transmis-
sion. Whether the first antibodies could protect if present in
sufficient quantities at the time of transmission is a key ques-
tion. Since we and others have detected no neutralizing activity
of AHI gp41 antibodies, if most virions could be opsonized, the
anti-HIV-1 activity would have to be via nonneutralizing mech-
anisms, such as virion-inhibited movement across mucosal sur-
faces, antibody-mediated phagocytosis, or antibody-mediated
cellular cytotoxicity (25). The results from the RV144 HIV-1
vaccine trial in Thailand have raised the hypothesis that virus
inhibitory antibodies, other than traditional neutralizing anti-
bodies, might provide some protection, especially in low-risk
populations (36).
Our studies of immune complexes circulating in plasma dur-
ing AHI are consistent with our in vitro results, wherein puri-
fied plasma IgG from selected patients captured up to 76% of
infectious viruses. However, the IgG-bound virions likely rep-
resent a fraction of total circulating infectious virions in vivo.
This leads to the question of whether the initial antibody re-
sponse that forms ICs is ineffectual in controlling viral load
because it fails to capture all infectious virions or because the
initial nonneutralizing antibodies simply bind nonfunctional
Env but do not bind functional trimers on the virion surface.
Alternatively, the initial opsonization of virions may be inef-
fectual because they serve to promote infection by trafficking
antibody-coated virions to lymph nodes where viral replication
can be amplified. In acute simian immunodeficiency virus
(SIV) infection, the ratio of infectious virions to total virions is
highest in the ramp-up stage of plasma viremia (24, 45), sug-
gesting that there might be virion or virion-associated factors
that contribute to early SIV infectivity. Whether a similar phe-
nomenon is present in HIV-1 AHI is not known. However, all
evidence to date suggests that the initial antibody response to
gp41 is not a factor in the initial control of viremia. Further
work on the dynamics of infectious virions in acute HIV-1 is
needed to understand how observations of acute SIV infection
relate to acute HIV-1 infection.
Other studies have examined antibody-antigen complexes in
plasma from subjects infected with HIV-1 (35) but have fo-
cused on HIV-1 antigens and not on whole-virion binding to
antibody. We show in this report that the initial ICs in AHI
were comprised primarily of gp41 IgG and that gp120 antibod-
ies were not present in immune complexes during early AHI.
Importantly, anti-gp120 antibodies are not found circulating in
plasma during this time. The presence of gp41-specific anti-
bodies in immune complexes in AHI indicates that gp41 is
exposed on circulating virions in vivo. Thus, during AHI, the
presence of a nonfunctional envelope on circulating virions
could be the predominant antigen that helps to drive the initial
nonneutralizing antibody response.
Several studies have characterized the ability of anti-Env
monoclonal antibodies to capture both virions and infectious
virions (5, 16, 30, 31, 34). Burrer et al. found that gp41 Env
antibodies were responsible for virus capture in purified poly-
clonal plasma IgG (5). Poignard et al. demonstrated that the
envelope expressed on HIV-1 virions is heterogeneous, such
that both functional and nonfunctional envelope molecules are
present (34). Thus, virus capture can be mediated by binding to
FIG. 9. Percentage of virions bound in complexes at various antibody concentrations for 8 different patients. Red lines show the best fits to
patient data for a model with univalent binding (red dots), given by equation 1. Blue and green lines assume HIV has binding sites with f values
of 14 and 35, respectively. Estimates for the affinity constant K are given in Table S2 in the supplemental material. The aberrant fit of the model
to the data from patient 12008 could be explained by an extension of the model that assumes that two different strains of HIV-1 with different
affinities for anti-gp41 IgG are present in this patient (results not shown).
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the nonfunctional envelope spikes, leaving the infectious en-
velope spikes available for the measurement of infectious virus
as we showed in this current study. Consistent with this earlier
work (5, 28), we also found that the efficiency of virus capture
by purified polyclonal plasma IgG did not correlate with the
neutralizing activity, i.e., plasma that had no neutralizing ac-
tivity robustly captured virions.
Like the prototypic nonneutralizing gp41 immunodominant
region MAb, 7B2 (32), AHI anti-gp41 plasma IgG captured
both infectious and noninfectious virions. This is likely due to
the presence of nonfunctional Env protein on the surface of
virions in the form of gp120/gp41 monomers or gp41 stumps
(28). Anti-gp41 IgG can easily bind to gp41 stumps on the
surfaces of infectious or noninfectious virions and may explain
why the high percentage of plasma VL existed as circulating
IgG-virion IC. Unlike anti-gp41 IgG and HIVIG, 2G12 MAb
selectively captured infectious HIV-1, indicating that 2G12
MAb is selectively targeting the native functional Env spike
that is presented on the surface of infectious virions.
In summary, circulating plasma IgG-virion ICs were fre-
quently detected during AHI, accounted for a fraction of
circulating virions in most subjects examined, and were com-
prised of Env gp41-specific antibodies. These IgG gp41 virion-
binding antibodies either arise too late in the course of infec-
tion to control viremia, opsonize too few virions to mediate an
antiviral effect, or alternatively may contribute to virus repli-
cation.
ACKNOWLEDGMENTS
This work was supported by the National Institutes of Health (NIH/
NIAID/DAIDS) Center for HIV/AIDS Vaccine Immunology Grant
(U01 AI067854). The funders had no role in study design, data col-
lection and analysis, decision to publish, or preparation of the manu-
script.
We are indebted to the CHAVI 001 clinical teams and patients for
their numerous contributions that were central to this study. We also
thank Kelly Soderberg and Jennifer Kirchherr for program support,
Shelley Stewart, Judith T. Lucas, and Vicki C. Ashley for technical
assistance, Hua-Xin Liao for HIV-1 gp140 envelope proteins, Cristine
Cooper, SCHARP, for statistical support, and Michael Frank, Xiaoy-
ing Shen, Robert C. Schutte, and Genevieve Fouda for helpful discus-
sions.
REFERENCES
1. Alam, S. M., et al. 2008. Human immunodeficiency virus type 1 gp41 anti-
bodies that mask membrane proximal region epitopes: antibody binding
kinetics, induction, and potential for regulation in acute infection. J. Virol.
82:115–125.
2. Bajtay, Z., C. Speth, A. Erdei, and M. P. Dierich. 2004. Cutting edge:
productive HIV-1 infection of dendritic cells via complement receptor type
3 (CR3, CD11b/CD18). J. Immunol. 173:4775–4778.
3. Bouhlal, H., et al. 2002. Opsonization of HIV-1 by semen complement
enhances infection of human epithelial cells. J. Immunol. 169:3301–3306.
4. Bourinbaiar, A. S. 1994. The ratio of defective HIV-1 particles to replica-
tion-competent infectious virions. Acta Virol. 38:59–61.
5. Burrer, R., S. Haessig-Einius, A. M. Aubertin, and C. Moog. 2005. Neutral-
izing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from
infected patients capture HIV-1 via antibodies directed against the principal
immunodominant domain of gp41. Virology 333:102–113.
6. Calarese, D. A., et al. 2005. Dissection of the carbohydrate specificity of the
broadly neutralizing anti-HIV-1 antibody 2G12. Proc. Natl. Acad. Sci.
U. S. A. 102:13372–13377.
7. Dianzani, F., et al. 2002. Is human immunodeficiency virus RNA load com-
posed of neutralized immune complexes? J. Infect. Dis. 185:1051–1054.
8. Doria-Rose, N. A., et al. 2005. Human immunodeficiency virus type 1 subtype
B ancestral envelope protein is functional and elicits neutralizing antibodies
in rabbits similar to those elicited by a circulating subtype B envelope.
J. Virol. 79:11214–11224.
9. Edmonds, T. G., et al. 2010. Replication competent molecular clones of
HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhi-
bition in PBMC. Virology 408:1–13.
10. Faulkner, D. V., and J. Jurka. 1988. Multiple aligned sequence editor
(MASE). Trends Biochem. Sci. 13:321–322.
11. Fiebig, E. W., et al. 2003. Dynamics of HIV viremia and antibody serocon-
version in plasma donors: implications for diagnosis and staging of primary
HIV infection. AIDS 17:1871–1879.
12. Forthal, D. N., P. B. Gilbert, G. Landucci, and T. Phan. 2007. Recombinant
gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the
presence of Fc receptor-bearing effector cells and correlate inversely with
HIV infection rate. J. Immunol. 178:6596–6603.
13. Forthal, D. N., et al. 2007. FcgammaRIIa genotype predicts progression of
HIV infection. J. Immunol. 179:7916–7923.
14. Freel, S. A., et al. 2010. Phenotypic and functional profile of HIV-inhibitory
CD8 T cells elicited by natural infection and heterologous prime/boost vac-
cination. J. Virol. 84:4998–5006.
15. Gasper-Smith, N., et al. 2008. Induction of plasma (TRAIL), TNFR-2, Fas
ligand and plasma microparticles after HIV-1 transmission: implications for
HIV-1 vaccine design. J. Virol. 82:7700–7710.
16. Gorny, M. K., et al. 2002. Human monoclonal antibodies specific for con-
formation-sensitive epitopes of V3 neutralize human immunodeficiency vi-
rus type 1 primary isolates from various clades. J. Virol. 76:9035–9045.
17. Haynes, B. F., H. X. Liao, and G. D. Tomaras. 2010. Is developing an HIV-1
vaccine possible? Curr. Opin. HIV AIDS 5:362–367.
18. Jakubik, J. J., M. Saifuddin, D. M. Takefman, and G. T. Spear. 2000.
Immune complexes containing human immunodeficiency virus type 1 pri-
mary isolates bind to lymphoid tissue B lymphocytes and are infectious for T
lymphocytes. J. Virol. 74:552–555.
19. Keele, B. F., et al. 2008. Identification and characterization of transmitted
and early founder virus envelopes in primary HIV-1 infection. Proc. Natl.
Acad. Sci. U. S. A. 105:7552–7557.
20. Kimura, M. 1980. A simple method for estimating evolutionary rates of base
substitutions through comparative studies of nucleotide sequences. J. Mol.
Evol. 16:111–120.
21. Kirchherr, J. L., et al. 2007. High throughput functional analysis of HIV-1
env genes without cloning. J. Virol. Methods 143:104–111.
22. Leaman, D. P., H. Kinkead, and M. B. Zwick. 2010. In-solution virus capture
assay helps deconstruct heterogeneous antibody recognition of human im-
munodeficiency virus type 1. J. Virol. 84:3382–3395.
23. Liao, H. X., et al. 2009. High-throughput isolation of immunoglobulin genes
from single human B cells and expression as monoclonal antibodies. J. Virol.
Methods 158:171–179.
24. Ma, Z. M., et al. 2009. High specific infectivity of plasma virus from the
pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus
infection. J. Virol. 83:3288–3297.
25. McElrath, M. J., and B. F. Haynes. 2010. Induction of immunity to human
immunodeficiency virus type-1 by vaccination. Immunity 33:542–554.
26. McMichael, A. J., P. Borrow, G. D. Tomaras, N. Goonetilleke, and B. F.
Haynes. 2010. The immune response during acute HIV-1 infection: clues for
vaccine development. Nat. Rev. Immunol. 10:11–23.
27. Moir, S., et al. 2000. B cells of HIV-1-infected patients bind virions through
CD21-complement interactions and transmit infectious virus to activated T
cells. J. Exp. Med. 192:637–646.
28. Moore, P. L., et al. 2006. Nature of nonfunctional envelope proteins on the
surface of human immunodeficiency virus type 1. J. Virol. 80:2515–2528.
29. Morrow, W. J., M. Wharton, R. B. Stricker, and J. A. Levy. 1986. Circulating
immune complexes in patients with acquired immune deficiency syndrome
contain the AIDS-associated retrovirus. Clin. Immunol. Immunopathol. 40:
515–524.
30. Nyambi, P. N., et al. 2000. Conserved and exposed epitopes on intact, native,
primary human immunodeficiency virus type 1 virions of group M. J. Virol.
74:7096–7107.
31. Perez-Bercoff, D., A. David, H. Sudry, F. Barre-Sinoussi, and G. Pancino.
2003. Fcgamma receptor-mediated suppression of human immunodeficiency
virus type 1 replication in primary human macrophages. J. Virol. 77:4081–
4094.
32. Pincus, S. H., et al. 2003. In vivo efficacy of anti-glycoprotein 41, but not
anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection.
J. Immunol. 170:2236–2241.
33. Platt, E. J., S. L. Kozak, J. P. Durnin, T. J. Hope, and D. Kabat. 2010. Rapid
dissociation of HIV-1 from cultured cells severely limits infectivity assays,
causes the inactivation ascribed to entry inhibitors, and masks the inherently
high level of infectivity of virions. J. Virol. 84:3106–3110.
34. Poignard, P., et al. 2003. Heterogeneity of envelope molecules expressed on
primary human immunodeficiency virus type 1 particles as probed by the
binding of neutralizing and nonneutralizing antibodies. J. Virol. 77:353–365.
35. Portera, M., et al. 1990. Free and antibody-complexed antigen and antibody
profile in apparently healthy HIV seropositive individuals and in AIDS
patients. J. Med. Virol. 30:30–35.
36. Rerks-Ngarm, S., et al. 2009. Vaccination with ALVAC and AIDSVAX to
prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209–2220.
37. Saifuddin, M., et al. 1995. Role of virion-associated glycosylphosphatidyl-
11206 LIU ET AL. J. VIROL.
inositol-linked proteins CD55 and CD59 in complement resistance of cell
line-derived and primary isolates of HIV-1. J. Exp. Med. 182:501–509.
38. Saitou, N., and M. Nei. 1987. The neighbor-joining method: a new method
for reconstructing phylogenetic trees. Mol. Biol. Evol. 4:406–425.
39. Shen, X., et al. 2010. Prolonged exposure of the HIV-1 gp41 membrane
proximal region with L669S substitution. Proc. Natl. Acad. Sci. U. S. A.
107:5972–5977.
40. Stacey, A. R., et al. 2009. Induction of a striking systemic cytokine cascade
prior to peak viremia in acute human immunodeficiency virus type 1 infec-
tion, in contrast to more modest and delayed responses in acute hepatitis B
and C virus infections. J. Virol. 83:3719–3733.
41. Thompson, J. D., D. G. Higgins, and T. J. Gibson. 1994. CLUSTAL W:
improving the sensitivity of progressive multiple sequence alignment through
sequence weighting, position-specific gap penalties and weight matrix choice.
Nucleic Acids Res. 22:4673–4680.
42. Tomaras, G. D., and B. F. Haynes. 2009. HIV-1-specific antibody responses
during acute and chronic HIV-1 infection. Curr. Opin. HIV AIDS 4:373–
379.
43. Tomaras, G. D., and B. F. Haynes. 2010. Strategies for eliciting HIV-1
inhibitory antibodies. Curr. Opin. HIV AIDS 5:421–427.
44. Tomaras, G. D., et al. 2008. Initial B-cell responses to transmitted human
immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and
IgG antibodies followed by plasma anti-gp41 antibodies with ineffective
control of initial viremia. J. Virol. 82:12449–12463.
45. Vaidya, N. K., R. M. Ribeiro, C. J. Miller, and A. S. Perelson. 2010. Viral
dynamics during primary simian immunodeficiency virus infection: effect of
time-dependent virus infectivity. J. Virol. 84:4302–4310.
46. Wang, L. X., J. Ni, S. Singh, and H. Li. 2004. Binding of high-mannose-
type oligosaccharides and synthetic oligomannose clusters to human an-
tibody 2G12: implications for HIV-1 vaccine design. Chem. Biol. 11:127–
134.
47. Zhu, P., et al. 2006. Distribution and three-dimensional structure of AIDS
virus envelope spikes. Nature 441:847–852.
VOL. 85, 2011 ACUTE HIV-1 INFECTION IMMUNE COMPLEXES 11207
